Bliss GVS Pharma Limited has informed the Exchange about change in Management
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The filing is a Board Meeting outcome dated May 12, 2026. Key highlights: (1) Audited standalone net profit of ₹3,242.25 lakh and consolidated net profit of ₹9,687.44 lakh for FY ended March 31, 2026 — strong growth driven by pharma exports and new subsidiary additions in Kenya and DRC; (2) Unmodified audit opinion issued by Kalyaniwalla & Mistry LLP on both standalone and consolidated results; (3) Board recommended a final dividend of ₹1 per share (100% payout) subject to shareholder approval at the 41st AGM on July 15, 2026; (4) Reappointed BDO India Services Private Limited as Internal Auditor for FY 2026-27; (5) During the year, the company incorporated two new step-down subsidiaries (Theralife Pharma Ltd in Kenya and Theralife Pharma RDC Private Limited in DRC). The headline reference to 'change in management' appears to be a mismatch — no management or director changes are mentioned in the document.
No management change was actually disclosed. The results reflect solid earnings growth and a shareholder-friendly dividend. The expansion into new geographies (Kenya, DRC) signals a positive strategic direction.